Interpace Biosciences Sets $6.00–$7.00 Price Range for 3.1M-Share Nasdaq Uplist Offering
Summary
Interpace Biosciences filed an amended S-1 setting a $6.00–$7.00 per share price range for its 3.1 million share firm commitment offering, with Lake Street Capital Markets as underwriter. Net proceeds are estimated at $17.9 million, and the offering is contingent on Nasdaq listing approval.
Key Events · Financing and Capital Events · IDXGD
-
Offering Priced at $6.00–$7.00
The amended S-1 sets a public offering price range of $6.00 to $7.00 per share for 3,100,000 shares, with a midpoint of $6.50. The last reported OTCID sale price on September 29, 2026 was $6.42.
-
Net Proceeds Estimated at $17.9M
After deducting the 6.0% underwriting discount ($0.39 per share) and estimated $1.0 million in offering expenses, net proceeds are approximately $17.9 million, or $20.8 million if the 465,000-share over-allotment option is fully exercised.
-
Nasdaq Listing Contingency
The offering closing is contingent on receiving conditional approval from Nasdaq for listing under the symbol 'IDXG'. The company currently trades on the OTCID and completed a 1-for-5 reverse stock split on August 27, 2026 to meet Nasdaq's minimum bid price requirement.
-
Dilution to New Investors
At the $6.50 midpoint, new investors would experience immediate dilution of $2.03 per share in net tangible book value, while existing stockholders would see an increase of $0.69 per share.
Analysis · IDXGD · Industrial Applications And Services
The pricing range for Interpace Biosciences' firm commitment offering is now finalized at $6.00 to $7.00 per share, with Lake Street Capital Markets acting as sole bookrunner. Expected net proceeds of approximately $17.9 million will fund working capital, capital expenditures, and development of new pancreatic and Barrett's Esophagus diagnostic tests. The offering hinges on Nasdaq listing approval, and the company recently completed a 1-for-5 reverse stock split to satisfy the minimum bid price requirement. With 3.1 million shares on offer against the current 5.9 million shares outstanding, existing shareholders face meaningful dilution, though the capital provides runway for the company's thyroid-focused diagnostic business.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IDXGD was trading at $6.47 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $35.8M. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.